triazoles has been researched along with paclitaxel in 47 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (2.13) | 18.2507 |
2000's | 15 (31.91) | 29.6817 |
2010's | 24 (51.06) | 24.3611 |
2020's | 7 (14.89) | 2.80 |
Authors | Studies |
---|---|
Chen, PS | 1 |
Inada, S; Shimmen, T | 1 |
Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA | 1 |
Bauer, KS; Bostick-Bruton, F; Figg, WD; Fuse, E; Goldspiel, B; Kohn, EC; Kulpa, V; Liotta, LA; Minasian, L; Noone, M; Pluda, J; Reed, E; Sarosy, GA; Tompkins, A | 1 |
Burstein, HJ; Winer, EP | 1 |
Mokbel, K; Singh-Ranger, G | 1 |
Baraldi, PG; Borea, PA; Capitani, S; Gessi, S; Leung, E; Merighi, S; Mirandola, P; Tabrizi, MA; Varani, K | 1 |
Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R | 1 |
Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H | 1 |
Endo, W; Fujie, Y; Fukunaga, H; Hojo, S; Maeura, Y; Okada, Y; Ota, H; Yoshioka, S | 1 |
Berstein, LM; Bozhok, AA; Dashyan, GA; Ivanov, VG; Kletzel, A; Melnikova, OA; Paltuev, RM; Semiglazov, VF; Semiglazov, VV; Ziltsova, EK | 1 |
Bershteĭn, LM; Bozhok, AA; Damenia, AO; Dashian, GA; Donskikh, RV; Ivanov, VG; Klettsel', AA; Kochetova, IA; Krivorot'ko, PV; Mel'nikova, OA; Paltuev, RM; Semiglazov, VF; Semiglazov, VV; Tonuzov, EE; Voskresenskiĭ, DA; Zernov, KIu; Zhil'tsova, EK | 1 |
Barnett, J; Cuthbertson, A; Morrison, MS; Ricketts, SA; Tessier, J; Wedge, SR | 1 |
Ayral-Kaloustian, S; Beyer, CF; Gibbons, JJ; Hernandez, R; Nguyen, T; Vitale, D; Zhang, N | 1 |
Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
Kaide, A; Kodama, K; Matsuoka, J; Ootawa, Y; Ootsuka, N; Watanabe, N | 1 |
Azad, N; Figg, WD; Gardner, E; Graves, C; Imamura, CK; Kohn, EC; Kotz, H; Minasian, L; Perroy, A; Raggio, M; Sarosy, GA | 1 |
Brewster, ME; Danhier, F; Magotteaux, N; Préat, V; Ucakar, B | 1 |
Abe, M; Kiniwa, M; Matsuo, K; Nakagawa, F; Noguchi, S; Nukatsuka, M; Saito, H; Shibata, J; Uchida, J | 1 |
Amano, S; Enomoto, K; Sakurai, K | 1 |
Amano, S; Enomoto, K; Fujisaki, S; Hara, Y; Maeda, T; Nagashima, S; Sakurai, K; Shibata, M; Ueda, Y | 1 |
Blackman, RK; Foley, KP; He, S; Koya, K; Liu, Y; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Wada, Y; Ye, S; Zhang, C; Zhou, D | 1 |
Gradishar, WJ | 1 |
Aogi, K; Fujisawa, T; Fukuda, H; Inoue, K; Iwata, H; Kinoshita, T; Masuda, N; Nakamura, K; Shibata, T; Shien, T | 1 |
Astsaturov, I; Connolly, DC; Golemis, EA; Litwin, S; Liu, H; Maglaty, MA; Martin, LP; O'Brien, SW; Proia, DA; Serebriiskii, IG; Xiao, F | 1 |
Chen, ML; Li, K; Zhang, J; Zhu, ZL | 1 |
Marchitti, SA; Mazur, CS; Zastre, J | 1 |
Huang, W; Jiao, L; Li, Y; Liu, B; Qian, H; Qiu, Q; Zhao, T | 1 |
Kitamura, T; Tanaka, Y; Tsuboi, K; Tsuda, S; Tsujii, S; Yagi, K; Yamamoto, A | 1 |
Antolín-Novoa, S; Antón, A; Blanco-Campanario, E; de la Cruz-Merino, L; Galán-Brotons, A; Gallegos-Sancho, MI; Murías-Rosales, A; Peláez, I; Pérez-Carrión, R | 1 |
Bozhok, AA; Dashyan, GA; Komyakhov, AV; Lalak, IA; Manikhas, AG; Paltuev, RM; Petrenko, OL; Semiglazov, VF; Semiglazov, VV; Semiglazova, TY | 1 |
Bosenberg, MW; Held, MA; Iyidogan, P; Langdon, CG; Levy, F; Mamillapalli, R; Platt, JT; Stern, DF; Theodosakis, N; Vuagniaux, G; Wang, S; Wiedemann, N | 1 |
Agyeman, AS; Conzen, SD; Jun, WJ; Kim, CR; Kocherginsky, M; Proia, DA; Skor, MN | 1 |
Amico, AL; Olopade, OI; Saha, P | 1 |
Diao, L; Komaki, R; Lin, SH; Liu, H; Potter, A; Proia, DA; Qiao, Y; Tailor, R; Wang, J; Wang, Y; Zhang, J | 1 |
Bősze, S; Csámpai, A; Dinić, J; Hudecz, F; Kocsis, L; Pešić, M; Podolski-Renić, A | 1 |
Fuh, KC; Guo, L; Hagemann, AR; Hagemann, IS; McCourt, CK; Mutch, DG; Palisoul, ML; Powell, MA; Quinn, JM; Reger, K; Schepers, E; Thaker, PH | 1 |
Beck-Noia, H; Fuh, KC; Greenwade, MM; Guo, L; Hagemann, AR; Hagemann, IS; Massad, K; McCourt, CK; Mutch, DG; Opara, G; Palisoul, ML; Powell, MA; Quinn, JM; Thaker, PH; Zhao, P | 1 |
Ishihara, T; Kakugo, A; Konagaya, A; Nasrin, SR; Rashedul Kabir, AM; Sada, K | 1 |
Cai, Z; Lai, H; Li, S; Li, Y; Liu, Y; Shi, Q; Wang, R | 1 |
Anderhub, SJ; Blagg, J; Burke, R; Drosopoulos, K; Eccles, SA; Faisal, A; Filosto, S; Gurden, MD; Hayes, A; Hoelder, S; Innocenti, P; Linardopoulos, S; Mak, GW; Naud, S; Raynaud, FI; Saville, H; Theofani, E; van Montfort, RLM; Walsh, K; Westwood, IM; Woodward, HL | 1 |
Du, J; Gao, M; Guan, Q; Li, J; Li, Z; Liu, T; Wu, Y; Zhang, W; Zuo, D | 1 |
Brown, M; Fassl, A; Ge, JY; Gulvady, A; Heavey, GA; Jovanović, B; Kuang, Y; Kwon, M; Luoma, A; McDonald, TO; Michor, F; Murphy, K; Paweletz, C; Pellman, D; Polyak, K; Qi, J; Shu, S; Sicinski, P; Thorner, AR; Trinh, A; Wucherpfennig, KW | 1 |
Chen, J; Cheng, Z; Luo, J; Meng, Y; Sun, T; Wang, X; Xia, B; Zhang, Z; Zhou, X | 1 |
Carter, BW; Colen, R; Fu, S; Gong, J; Hong, DS; Janku, F; Karp, DD; McQuinn, L; Meric-Bernstam, F; Milton, DR; Naing, A; Piha-Paul, SA; Shah, J; Stephen, BA; Sulovic, S; Thein, KZ; Tsimberidou, A; Yap, TA | 1 |
Bagiński, M; Bartoszewski, R; Dąbrowska, AM; Filip-Psurska, B; Gawrońska, M; Krzymiński, K; Milczarek, M; Moszyńska, A; Psurski, M; Świtalska, M; Wietrzyk, J | 1 |
Castellano, GM; Garbuzenko, OB; Malhotra, J; Minko, T; Pine, SR; Sabaawy, HE; Zeeshan, S | 1 |
2 review(s) available for triazoles and paclitaxel
Article | Year |
---|---|
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
7 trial(s) available for triazoles and paclitaxel
Article | Year |
---|---|
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Middle Aged; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Recurrence; Time Factors; Treatment Outcome; Triazoles; Tumor Cells, Cultured | 2001 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Nitriles; Paclitaxel; Postmenopause; Receptors, Estrogen; Triazoles | 2007 |
[Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Doxorubicin; Female; Humans; Mammography; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2007 |
A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome; Triazoles; Young Adult | 2009 |
A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Tamoxifen; Trastuzumab; Triazoles; Young Adult | 2012 |
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Everolimus; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Triazoles | 2015 |
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Hydrazines; Lung Neoplasms; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Triazoles; Vomiting | 2022 |
38 other study(ies) available for triazoles and paclitaxel
Article | Year |
---|---|
Biotechnology transfer at the National Institutes of Health.
Topics: Aminoimidazole Carboxamide; Antineoplastic Agents; Biotechnology; Ethics, Medical; Humans; Industry; National Institutes of Health (U.S.); Paclitaxel; Proteins; Research; Research Support as Topic; Technology Transfer; Tissue Inhibitor of Metalloproteinase-2; Triazoles; United States | 1993 |
Regulation of elongation growth by gibberellin in root segments of Lemna minor.
Topics: Cell Size; Dose-Response Relationship, Drug; Gibberellins; Indoleacetic Acids; Magnoliopsida; Microtubules; Paclitaxel; Plant Growth Regulators; Plant Roots; Triazoles | 2000 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration | 2001 |
Advances in breast oncology: the 2002 ASCO meeting.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Docetaxel; Evidence-Based Medicine; Female; Humans; Nitriles; Paclitaxel; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Technology Assessment, Biomedical; Triazoles | 2002 |
Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine.
Topics: Antineoplastic Agents; Cell Cycle; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Keratinocytes; Melanoma; Paclitaxel; Purinergic P1 Receptor Antagonists; Pyrimidines; Receptor, Adenosine A3; Triazoles; Tumor Cells, Cultured; Vindesine | 2003 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Administration Schedule; Female; Floxuridine; Humans; Hysterotomy; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Nitriles; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Triazoles | 2005 |
[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Invasiveness; Nitriles; Paclitaxel; Skin Neoplasms; Sternum; Triazoles | 2005 |
[Two patients having recurrent breast cancer with brain metastases well controlled with a gamma knife radio-surgery].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Pleurisy; Pleurodesis; Radiosurgery; Triazoles | 2006 |
Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Mice; Neoplasms; Oligopeptides; Paclitaxel; Peptides; Polyethylene Glycols; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tissue Distribution; Triazoles | 2009 |
The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties.
Topics: Antineoplastic Agents; Biopolymers; Cold Temperature; Flow Cytometry; Guanosine Triphosphate; HeLa Cells; Humans; Hydrocarbons, Halogenated; Microtubules; Paclitaxel; Radioligand Assay; Triazoles; Tubulin; Vincristine | 2009 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles | 2009 |
Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Nitriles; Paclitaxel; Postmenopause; Treatment Outcome; Triazoles; Tumor Burden | 2010 |
Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Synergism; HeLa Cells; Humans; Lactones; Liver Neoplasms, Experimental; Mice; Mice, Inbred Strains; Micelles; Nanoparticles; Paclitaxel; Particle Size; Polyesters; Polyglactin 910; Protein Kinase Inhibitors; Solubility; Surface Properties; Triazoles; Xenograft Model Antitumor Assays | 2010 |
Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Combinations; Estrogen Receptor alpha; Estrogens; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oxonic Acid; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tegafur; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured; Uracil | 2011 |
[Indoleamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Letrozole; Middle Aged; Nitriles; Paclitaxel; Triazoles; Tryptophan | 2010 |
[Long-term follow-up study: indolemamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Hormone Replacement Therapy; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Letrozole; Middle Aged; Nitriles; Paclitaxel; Time Factors; Triazoles | 2011 |
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Combinations; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Paclitaxel; Taxoids; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Female; Flow Cytometry; Gene Regulatory Networks; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Mice, Transgenic; Ovarian Neoplasms; Paclitaxel; Protein Array Analysis; RNA, Small Interfering; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Letrozole; Meta-Analysis as Topic; Nitriles; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Triazoles | 2013 |
P-glycoprotein inhibition by the agricultural pesticide propiconazole and its hydroxylated metabolites: Implications for pesticide-drug interactions.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Biotransformation; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxylation; Mice; NIH 3T3 Cells; Paclitaxel; Pesticides; Risk Assessment; Transfection; Triazoles | 2015 |
6,7-Dimethoxy-2-{2-[4-(1H-1,2,3-triazol-1-yl)phenyl]ethyl}-1,2,3,4-tetrahydroisoquinolines as superior reversal agents for P-glycoprotein-mediated multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Cell Survival; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Daunorubicin; Drug Resistance, Neoplasm; Humans; K562 Cells; Paclitaxel; Protein Binding; Rhodamine 123; Structure-Activity Relationship; Tetrahydroisoquinolines; Triazoles; Vincristine | 2015 |
[Long-term survival of a breast cancer patient with carcinomatous pleuritis and carcinomatous cardiac tamponade successfully treated by multimodality therapy].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cardiac Tamponade; Combined Modality Therapy; Female; Humans; Letrozole; Nitriles; Paclitaxel; Pleurisy; Triazoles | 2015 |
Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Letrozole; Middle Aged; Nitriles; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2015 |
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azepines; Azocines; Benzhydryl Compounds; Camptothecin; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Paclitaxel; Signal Transduction; Taxoids; Time Factors; Topoisomerase Inhibitors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Mice; Paclitaxel; Receptors, Glucocorticoid; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carmustine; Chemoradiotherapy; Craniotomy; Cyclophosphamide; Decanoic Acids; Disease-Free Survival; Doxorubicin; Female; Humans; Leuprolide; Nitriles; Paclitaxel; Polyesters; Radiosurgery; Receptors, Estrogen; Triazoles; Young Adult | 2016 |
Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
Topics: A549 Cells; Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemoradiotherapy; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Radiation-Sensitizing Agents; Triazoles; Xenograft Model Antitumor Assays | 2016 |
Ferrocene-cinchona hybrids with triazolyl-chalcone linkers act as pro-oxidants and sensitize human cancer cell lines to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Chalcones; Cinchona; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Ferrous Compounds; Humans; Lung Neoplasms; Metallocenes; Oxidants; Paclitaxel; Reactive Oxygen Species; Triazoles; Tumor Cells, Cultured | 2017 |
Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Proliferation; Drug Synergism; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Triazoles; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Topics: Animals; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Triazoles; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
Stabilization of microtubules by cevipabulin.
Topics: Animals; Hydrocarbons, Halogenated; Microscopy, Fluorescence; Microtubules; Molecular Docking Simulation; Molecular Structure; Nanotechnology; Paclitaxel; Protein Stability; Swine; Time-Lapse Imaging; Triazoles; Tubulin | 2019 |
LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Topics: Antineoplastic Agents; Apoptosis; Azepines; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mitosis; Nuclear Proteins; Paclitaxel; Protein Kinase Inhibitors; Triazoles; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins; Up-Regulation | 2020 |
High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers.
Topics: Animals; Biological Availability; Cell Cycle; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chromosome Segregation; Chromosomes, Human; Drug Synergism; Humans; Mice; Paclitaxel; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyrimidines; Spindle Apparatus; Triazoles; Triple Negative Breast Neoplasms | 2019 |
MAY, a novel tubulin inhibitor, induces cell apoptosis in A549 and A549/Taxol cells and inhibits epithelial-mesenchymal transition in A549/Taxol cells.
Topics: A549 Cells; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle Checkpoints; Cell Survival; Epithelial-Mesenchymal Transition; Humans; Inhibitory Concentration 50; Microtubules; Mitochondria; Nuclear Proteins; Paclitaxel; Polymerization; Signal Transduction; Triazoles; Tubulin Modulators; Twist-Related Protein 1 | 2020 |
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.
Topics: Animals; Azepines; Cell Cycle Checkpoints; Cell Proliferation; Clone Cells; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Mice; Models, Biological; Mutation; Paclitaxel; Piperazines; Ploidies; Proteins; Pyridines; Retinoblastoma Protein; Treatment Outcome; Triazoles; Triple Negative Breast Neoplasms; Up-Regulation | 2020 |
BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heterocyclic Compounds, 4 or More Rings; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Paclitaxel; Prognosis; Signal Transduction; Transcription Factors; Triazoles | 2021 |
Combined anticancer therapy with imidazoacridinone analogue C-1305 and paclitaxel in human lung and colon cancer xenografts-Modulation of tumour angiogenesis.
Topics: Acridines; Apoptosis; Colonic Neoplasms; Heterografts; Humans; Lung; Lung Neoplasms; Paclitaxel; Triazoles | 2022 |
Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
Topics: Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; DNA; Humans; Lung; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; TOR Serine-Threonine Kinases; Triazoles | 2022 |